This page contains affiliate links. Read more.

Why Circio Could Be One of the Most Exciting Biotech Plays Right Now

I’ve followed biotech for a while, and every now and then a company pops up that feels like it’s riding a genuine wave of scientific progress rather than just hype.
Circio Holding ASA (listed on Oslo as CRNA, formerly TRVX) is one of those for me at the moment.

The Norwegian company, with its Swedish R&D arm at the Karolinska Institute, has pivoted hard into circular RNA technology. If you’ve heard about the mRNA revolution thanks to COVID vaccines, circular RNA (circRNA) is like the smarter, longer-lasting cousin that could fix some of the biggest headaches in gene therapy and beyond.

Read also Beyond the Fjords: Debunking 6 Common Myths About Norway

The Problem with Today’s Gene Therapies (and Why It Matters)

Traditional gene therapies often use adeno-associated viruses (AAV) or DNA vectors to deliver instructions for making a missing or defective protein. The problem? The instructions come as linear mRNA, which gets chewed up quickly by the body’s natural cleanup crew. That means, you often need high doses to get enough protein produced.

High doses can lead to toxicity, immune reactions, or side effects (especially in the liver).
Treatments can be insanely expensive to manufacture and administer.
Result? Many genetic diseases (think rare conditions affecting the heart, eyes, muscles, or central nervous system) still don’t have great options, or the therapies that exist are limited to a small number of patients because of cost and safety issues.

Circio’s circVec Technology -Simple Explanation Here’s where Circio gets interesting.

Their proprietary circVec platform is a clever genetic “cassette” that you insert into a DNA or viral vector (like AAV). Once inside the patient’s cells, it doesn’t produce regular linear mRNA. Instead, it makes circular RNA.
Why is that a big deal? Circular RNA has no free ends, so the enzymes that normally degrade mRNA can’t attack it as easily.
In preclinical studies, Circio has shown up to 15–50x higher protein expression and up to 70–75x longer durability compared to conventional mRNA-based systems.

Think of it like this: instead of giving the cell a short-lived note that says “make this protein,” you’re turning the cell into a mini factory that keeps producing for weeks, months, or potentially even longer from a single dose.

The technology is modular, meaning it can be tweaked for different tissues (heart, eye, spleen, etc.) and combined with existing delivery systems. They’ve already demonstrated strong results in animal models for heart and eye tissues, including impressive performance even at much lower doses (which could mean safer and cheaper treatments).

They also have an older immunotherapy side with oncolytic viruses and a KRAS-targeted cancer vaccine (TG01), but the real excitement right now is clearly the circRNA platform.

Why This Feels Exciting (Beyond the Science)

Huge Market Need! The gene therapy market is projected to grow rapidly, but it’s held back by exactly the issues Circio is trying to solve: potency, durability, safety, and cost. If circVec can help deliver more effective, lower-dose therapies, it could open the door to treating more patients and more diseases.

Platform Potential

This isn’t a one-drug story. circVec is a platform technology that can be licensed or partnered across gene therapy, cell therapy, and even chronic diseases. Big pharma is already paying attention. Circio recently entered a fully funded feasibility study with one of the world’s largest pharmaceutical companies.

Recent Momentum

The company just closed a significantly oversubscribed private placement raising around NOK 250 million, giving them a cash runway into 2030.
That’s a strong vote of confidence from investors and allows them to accelerate preclinical work and chase more partnerships.

They’re also the only publicly listed pure-play company heavily focused on this specific circular RNA expression approach, which gives public market investors rare access to an emerging field that’s otherwise mostly in private hands.

How Circio Could Actually Make Money

Circio isn’t planning to take every therapy all the way to market themselves (that would be capital-intensive and risky). Instead, they’re positioning circVec as a enabling technology:
Upfront payments and milestone payments from licensing deals or collaborations.
Royalties on future sales if partners use circVec in approved products.

This is a classic high-margin platform model. One or two solid deals with big pharma could bring in meaningful non-dilutive capital, while successful validation in key indications (like eye diseases or cardiac genetic conditions) could drive significant upside.
Of course, it’s still early -most of the data is preclinical, and biotech is full of risks (technical, regulatory, competition from other RNA or gene-editing approaches). But the recent big-pharma collaboration and strong in vivo results suggest they’re making real progress.

Bottom Line

Circio feels exciting because it sits at the intersection of two hot areas: the ongoing RNA revolution and the massive unmet need in gene therapy. Their circVec technology offers a relatively straightforward but powerful improvement -longer-lasting, stronger protein production with potentially better safety and lower costs.
If they can keep delivering data and secure more partnerships, this could evolve from a small Norwegian biotech into a key player whose technology ends up inside multiple approved therapies.

It’s definitely not without risk, and it’s a long-term story. But for investors who believe the next wave of genetic medicine needs better vectors and expression systems, Circio is worth keeping on the radar.

Sources:

This post is based on my own interests and opinions. Nothing here should be interpreted as investment advice…. Never Ever!!

Written by Dave 10. April 2026